Abstract
Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily. Engaging of BMPs to BMP receptors on the cell surface leads to activation of the receptor kinase activity, which phosphorylates Smad1/5/8. Smad1, 5, or 8, with Smad4, forms a complex, which is translocated to the nucleus, where it binds to the consensus DNA sequence to regulate the transcription of BMP target genes. BMP-Smad signaling regulates stem cell renewal, cell proliferation, differentiation, migration, and apoptosis, and controls embryo development and postnatal tissue homoeostasis. Both human and mouse genetic studies have demonstrated that BMPs play positive roles in postnatal bone homeostasis including osteoblast expansion, differentiation, and bone formation. Defects in BMP-Smad signaling cause bone-related disorders such as osteoporosis, a disease that affects hundreds of millions of people. In addition, BMP-Smad signaling has been shown to play an important role in tumorigenesis. Mounting evidence indicates that in many tissues, BMP-Smad signaling has a tumor-suppressing activity and that BMPs can repress tumor growth. These findings suggest that BMP-Smad pathway can be a potential target not only for osteoporosis therapy but also for cancer therapy.
Keywords: BMPs, Smad, genetics, osteoblast, osteoporosis, cancer, therapy, epithelia
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Volume: 8 Issue: 3
Author(s): Baojie Li
Affiliation:
Keywords: BMPs, Smad, genetics, osteoblast, osteoporosis, cancer, therapy, epithelia
Abstract: Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily. Engaging of BMPs to BMP receptors on the cell surface leads to activation of the receptor kinase activity, which phosphorylates Smad1/5/8. Smad1, 5, or 8, with Smad4, forms a complex, which is translocated to the nucleus, where it binds to the consensus DNA sequence to regulate the transcription of BMP target genes. BMP-Smad signaling regulates stem cell renewal, cell proliferation, differentiation, migration, and apoptosis, and controls embryo development and postnatal tissue homoeostasis. Both human and mouse genetic studies have demonstrated that BMPs play positive roles in postnatal bone homeostasis including osteoblast expansion, differentiation, and bone formation. Defects in BMP-Smad signaling cause bone-related disorders such as osteoporosis, a disease that affects hundreds of millions of people. In addition, BMP-Smad signaling has been shown to play an important role in tumorigenesis. Mounting evidence indicates that in many tissues, BMP-Smad signaling has a tumor-suppressing activity and that BMPs can repress tumor growth. These findings suggest that BMP-Smad pathway can be a potential target not only for osteoporosis therapy but also for cancer therapy.
Export Options
About this article
Cite this article as:
Li Baojie, Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/187153008785700127
DOI https://dx.doi.org/10.2174/187153008785700127 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Regulation of Endothelial Cell Death and Its Role in Angiogenesis and Vascular Regression
Current Neurovascular Research Bioactive Polyphenols from Healthy Diets and Forest Biomass
Current Nutrition & Food Science Aquaporin and Vascular Diseases
Current Neuropharmacology Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Current Cancer Drug Targets Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Diagnostic and Therapeutic Use of Human Recombinant Thyrotropin (rhTSH)(Thyrogen®) in Well-Differentiated Thyroid Cancer - Current Indications and Future Perspectives - A Review
Current Pharmaceutical Analysis Molecular Interplay between Platelets and the Vascular Wall in Thrombosis and Hemostasis
Current Vascular Pharmacology Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry GCPII Imaging and Cancer
Current Medicinal Chemistry AKT and cytosolic phospholipase A<sub>2</sub>α form a positive loop in prostate cancer cells
Current Cancer Drug Targets Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology Molecular Based Drug Targets for Idiopathic Pulmonary Fibrosis
Current Respiratory Medicine Reviews Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science